Literature DB >> 17724612

Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.

Hye-Jin Shin1, Joo-Young Kim, Chong-Woo Yoo, Stephen A Roberts, Sun Lee, Soo-Jin Choi, Hee-Young Lee, Doo-Hyun Lee, Tae Hyun Kim, Kwan Ho Cho.   

Abstract

PURPOSE: Carbonic anhydrase 9 (CA9) is over-expressed in many human solid tumors under conditions of low oxygen concentration and can be associated with a low probability of survival. In this study, stable CA9-expressing cell lines were established using the CA9 gene-defective human C33a cell line and the HeLa cell line to investigate the role of CA9 in response to ionizing radiation and hypoxia-selective cytotoxin, Tirapazamine (TPZ). METHODS AND MATERIALS: Human CA9 cDNA or an empty vector was transfected into the C33a and HeLa cell lines and C33a-vector, C33a-CA9, HeLa-vector, and HeLa-CA9 cell lines were produced accordingly. Sensitivity of the C33a-vector/C33a-CA9 cells to ionizing radiation and TPZ was measured using clonogenic assays. The alkaline comet assay was used to measure single strand DNA breaks caused by TPZ in the C33a-vector, C33a-CA9, HeLa-vector, and HeLa-CA9 cell lines.
RESULTS: Radiation sensitivity, as determined with clonogenic survival assays, of C33a-vector/C33a-CA9 cells did not differ under either normoxic or hypoxic conditions. However, increased clonogenic sensitivity to TPZ was observed in C33a-CA9 cells under the hypoxic condition by 26% (95% CI 14-39%, P = 0.02 in comparison to the C33a-vector cells). The comet assay showed significantly greater DNA damage in the C33a-CA9 cells compared with that of the C33a-vector cells with the same treatment under hypoxic conditions, supporting the results of the clonogenic survival data. Because this difference in the amount of DNA damage was not observed for the hypoxic HeLa-CA9/HeLa-vector cell lines, both of which have induced CA9 expression by hypoxia, the enhanced sensitivity of C33a-CA9 cells to TPZ is considered to be due to the specific condition of CA9 over-expression.
CONCLUSION: Our results suggest the possibility that CA9 over-expression in tumors might be exploited to increase the treatment effects of TPZ.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724612     DOI: 10.1007/s00432-007-0298-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

Authors:  Stephen K Williamson; John J Crowley; Primo N Lara; Jason McCoy; Derick H M Lau; Robert W Tucker; Glenn M Mills; David R Gandara
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

2.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

Authors:  S Ivanov; S Y Liao; A Ivanova; A Danilkovitch-Miagkova; N Tarasova; G Weirich; M J Merrill; M A Proescholdt; E H Oldfield; J Lee; J Zavada; A Waheed; W Sly; M I Lerman; E J Stanbridge
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 3.  E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.

Authors:  Charlotte Van Kesteren; Jos H Beijnen; Jan H M Schellens
Journal:  Anticancer Drugs       Date:  2002-11       Impact factor: 2.248

Review 4.  Carbonic anhydrases: current state of the art, therapeutic applications and future prospects.

Authors:  Silvia Pastorekova; Seppo Parkkila; Jaromir Pastorek; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2004-06       Impact factor: 5.051

5.  DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH.

Authors:  J H Tocher; N S Virk; D I Edwards
Journal:  Biochem Pharmacol       Date:  1990-09-15       Impact factor: 5.858

Review 6.  Tumor microenvironmental physiology and its implications for radiation oncology.

Authors:  Peter Vaupel
Journal:  Semin Radiat Oncol       Date:  2004-07       Impact factor: 5.934

7.  A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.

Authors:  Robert I Haddad; Lisa J Weinstein; Tad J Wieczorek; Nandita Bhattacharya; Harry Raftopoulos; Martin W Oster; Xinxin Zhang; Vaughan M Latham; Rosemary Costello; Jarrod Faucher; Carolyn DeRosa; Murray Yule; Linda P Miller; Massimo Loda; Marshall R Posner; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

8.  Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.

Authors:  Bronwyn G Siim; Frederik B Pruijn; Joanna R Sturman; Alison Hogg; Michael P Hay; J Martin Brown; William R Wilson
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

9.  Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.

Authors:  Joo-Young Kim; C M L West; H Valentine; T H Ward; A V Patterson; I J Stratford; S A Roberts; J H Hendry
Journal:  Radiother Oncol       Date:  2004-03       Impact factor: 6.280

10.  Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.

Authors:  B G Siim; P L van Zijl; J M Brown
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

View more
  3 in total

1.  Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.

Authors:  Bo Hong; Vivian W Y Lui; Edwin P Hui; Margaret H L Ng; Suk-Hang Cheng; Fion L Sung; Chi-Man Tsang; Sai-Wah Tsao; Anthony Tak-Cheung Chan
Journal:  Invest New Drugs       Date:  2009-12-16       Impact factor: 3.850

2.  Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.

Authors:  Arup Bhattacharya; Károly Tóth; Farukh A Durrani; Shousong Cao; Harry K Slocum; Sreenivasulu Chintala; Youcef M Rustum
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

3.  The genomic analysis of lactic acidosis and acidosis response in human cancers.

Authors:  Julia Ling-Yu Chen; Joseph E Lucas; Thies Schroeder; Seiichi Mori; Jianli Wu; Joseph Nevins; Mark Dewhirst; Mike West; Jen-Tsan Chi
Journal:  PLoS Genet       Date:  2008-12-05       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.